GSK Terminates Moncef Slaoui as Galvani Chair Over Sexual Harassment Allegations
GlaxoSmithKline (GSK) has announced that it has terminated Moncef Slaoui, former chief science adviser for Operation Warp Speed, as chairman of Galvani Bioelectronics — a company in which GSK is the majority shareholder — over sexual harassment allegations.
GSK said it made the decision after receiving a letter detailing the allegations and noted that an ongoing investigation substantiated the claims.
“Dr. Slaoui’s behaviors are wholly unacceptable,” GSK said. “They represent an abuse of his leadership position, violate company policies and are contrary to the strong values that define GSK’s culture.”
Slaoui could not be reached for comment.